Neurogene Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
Consolidated Statements of Operations
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue under licensing agreements | $925 | $— |
| Operating expenses: | ||
| Research and development expenses | 60,917 | 44,394 |
| General and administrative expenses | 22,613 | 11,189 |
| Total operating expenses | 83,530 | 55,583 |
| Loss from operations | (82,605) | (55,583) |
| Other income (expense): | ||
| Interest income | 8,467 | 2,951 |
| Interest expense | (12) | (12) |
| Other income | 574 | 16,355 |
| Other expense | (1,568) | (28) |
| Net loss | $(75,144) | $(36,317) |
| Pre-Merger · Post-Merger | |||||||
|---|---|---|---|---|---|---|---|
| Per share information (1): · (a) · (b) · (c) | |||||||
| Net income (loss) per share, basic | $(4.28) | $(117.28) | $— | $27.76 | |||
| Weighted-average shares outstanding used in computing net income (loss) per share, basic | 17,567,082 | 426,097 | — | 491,867 | |||
| Net income (loss) per share, diluted | $(4.28) | $(117.28) | $— | $2.93 | |||
| Weighted-average shares outstanding used in computing net income (loss) per share, diluted | 17,567,082 | 426,097 | — | 4,656,947 | |||
(1) On December 18, 2023, the Company completed its reverse merger, which among other things, resulted in Neurogene OpCo merging with and into a wholly owned subsidiary of Neoleukin Therapeutics, Inc. As the earnings per share information for the pre-merger period is not comparable to the earnings per share information for the post-merger period, the earnings per share information is being presented separately for these periods. See Note 3, Net Income (Loss) Per share, for additional information.
(a)Presents information for the pre-merger period for Class A common stock. The pre-merger period is January 1, 2023 through December 17, 2023 for the year ended December 31, 2023.
(b)Presents information for the pre-merger period for Class B common stock. The pre-merger period is January 1, 2023 through December 17, 2023 for the year ended December 31, 2023.
(c)Presents information for the post-merger period for common stock. The post-merger period is December 18, 2023 through December 31, 2023.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.